Protalix BioTherapeutics (PLX) SEC Filings & 10K Form $1.69 +0.06 (+3.68%) (As of 11/20/2024 ET) Add Compare Share Share SEC Filings Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Recent Protalix BioTherapeutics SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel DateFilerForm TypeView11/14/20246:03 AMProtalix BioTherapeutics (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 11/14/20245:57 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/05/20244:00 PMProtalix BioTherapeutics (Issuer)Rubin Eyal (Reporting)Form 4/A10/25/20243:23 PMProtalix BioTherapeutics (Subject)WHITEBOX ADVISORS LLC (Filed by)Form SC 13G/A10/25/20247:27 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 09/24/20244:00 PMNaos Yaron (Reporting)Protalix BioTherapeutics (Issuer)Form 4Statement of changes in beneficial ownership of securities 09/24/20244:00 PMProtalix BioTherapeutics (Issuer)Rubin Eyal (Reporting)Form 4Statement of changes in beneficial ownership of securities 08/14/20246:02 AMProtalix BioTherapeutics (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 08/14/20245:56 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 05/10/20246:20 AMProtalix BioTherapeutics (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 05/10/20245:59 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 04/03/20244:30 PMBashan Dror (Reporting)Protalix BioTherapeutics (Issuer)Form 4Statement of changes in beneficial ownership of securities 03/14/20246:03 AMProtalix BioTherapeutics (Filer)Form 10-KAnnual report pursuant to Section 13 or 15(d) 03/14/20245:57 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 01/02/20245:36 AMNACHT MARIUS (Filed by)Protalix BioTherapeutics (Subject)Form SC 13G/A12/26/20235:56 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies ZVRA SEC Filings ESPR SEC Filings RGNX SEC Filings SLRN SEC Filings MGTX SEC Filings XERS SEC Filings SIGA SEC Filings RNAC SEC Filings AURA SEC Filings AQST SEC Filings SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NYSE:PLX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
